5-trans Prostaglandin E2,
5-trans-PGE2,
36150-00-2,
5-trans-Prostaglandin E2,
UNII-6V30L285LP,
6V30L285LP,
9-oxo-11R,15S-dihydroxy-5E,13E-prostadienoic acid,
trans-Dinoprostone,
5,6-trans-PGE2,
5,6-trans-Dinoprostone,
Alprostadil impurity H [EP],
Dinoprostone specified impurity C [EP],
PGE2, 5,6-trans,
AC1NR1K1,
Dinoprostone impurity, 5,6-trans-dinoprostone- [USP],
HMS3648F17,
1463AH,
BDBM50213982,
LMFA03010148,
PDSP2_001531,
ZINC12503216,
Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5E,11alpha,13E,15S)-,
(E)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3S)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid,
SR-01000946421,
SR-01000946421-1,
(E)-7-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid,
(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid,
8-isoprostaglandin E2,
Dinoprostone EP Impurity C,
5-TRANSPROSTAGLANDINE2,
FA(20:2(OH2,Ke,cyclo)),
C20H32O5,
CID5283116,
CS-O-11875,